JP2012517449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517449A5 JP2012517449A5 JP2011549357A JP2011549357A JP2012517449A5 JP 2012517449 A5 JP2012517449 A5 JP 2012517449A5 JP 2011549357 A JP2011549357 A JP 2011549357A JP 2011549357 A JP2011549357 A JP 2011549357A JP 2012517449 A5 JP2012517449 A5 JP 2012517449A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- release composition
- sustained release
- minss
- improvement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002459 sustained Effects 0.000 claims 13
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-Aminopyridine Chemical group NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 4
- 229960004979 fampridine Drugs 0.000 claims 4
- 230000002045 lasting Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000005021 gait Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Claims (16)
- 多発性硬化症患者において歩行の改善を少なくとも1年持続させるための4-アミノピリジンの持続放出組成物であって、該組成物は、4-アミノピリジンの10ミリグラムの投与量で1日2回投与される持続放出組成物。
- 多発性硬化症患者において歩行の改善を少なくとも1年持続させるための医薬品を製造するための4-アミノピリジンの持続放出組成物の使用であって、該組成物は、4-アミノピリジンの10ミリグラムの投与量で1日2回投与される使用。
- 改善を少なくとも１８月持続させるための、請求項１に記載の組成物。
- 改善を少なくとも２年持続させるための、請求項１または３に記載の組成物。
- 歩行の改善が歩行速度の増大である、請求項１、３または４に記載の組成物。
- 持続放出組成物が、少なくとも11、12、13、14、15、16、17、18、19又は20ng/mlのCminssを達成する、請求項1および３〜５のいずれか１項に記載の組成物。
- 持続放出組成物が、約20ng/mlのCminssを達成する、請求項1および３〜５のいずれか１項に記載の組成物。
- 持続放出組成物が、約13から15ng/mlの範囲のCminssを達成する、請求項1および３〜５のいずれか１項に記載の組成物。
- 持続放出組成物が、12から20ng/mlの範囲のCminssを達成する、請求項1および３〜５のいずれか１項に記載の組成物。
- 改善を少なくとも１８月持続させるための、請求項２に記載の使用。
- 改善を少なくとも２年持続させるための、請求項２または１０に記載の使用。
- 歩行の改善が歩行速度の増大である、請求項２、１０または１１に記載の使用。
- 持続放出組成物が、少なくとも11、12、13、14、15、16、17、18、19又は20ng/mlのCminssを達成する、請求項２および１０−１２のいずれか１項に記載の使用。
- 持続放出組成物が、約20ng/mlのCminssを達成する、請求項２および１０−１２のいずれか１項に記載の使用。
- 持続放出組成物が、約13から15ng/mlの範囲のCminssを達成する、請求項２および１０〜１２のいずれか１項に記載の使用。
- 持続放出組成物が、12から20ng/mlの範囲のCminssを達成する、請求項２および１０〜１２のいずれか１項に記載の使用。
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15167909P | 2009-02-11 | 2009-02-11 | |
| US61/151,679 | 2009-02-11 | ||
| US25956309P | 2009-11-09 | 2009-11-09 | |
| US61/259,563 | 2009-11-09 | ||
| US28587209P | 2009-12-11 | 2009-12-11 | |
| US61/285,872 | 2009-12-11 | ||
| US28895309P | 2009-12-22 | 2009-12-22 | |
| US61/288,953 | 2009-12-22 | ||
| US29925910P | 2010-01-28 | 2010-01-28 | |
| US61/299,259 | 2010-01-28 | ||
| PCT/US2010/023970 WO2010093839A1 (en) | 2009-02-11 | 2010-02-11 | Compositions and methods for extended therapy with aminopyridines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012517449A JP2012517449A (ja) | 2012-08-02 |
| JP2012517449A5 true JP2012517449A5 (ja) | 2013-03-21 |
Family
ID=42562065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549357A Pending JP2012517449A (ja) | 2009-02-11 | 2010-02-11 | アミノピリジンによる長期治療のための組成物及び方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20120029035A1 (ja) |
| JP (1) | JP2012517449A (ja) |
| KR (3) | KR20120000560A (ja) |
| CN (2) | CN102046174A (ja) |
| AR (1) | AR075413A1 (ja) |
| AU (2) | AU2010213663A1 (ja) |
| BR (2) | BRPI1000030A2 (ja) |
| CA (1) | CA2751581A1 (ja) |
| CL (1) | CL2011001927A1 (ja) |
| CO (1) | CO6440534A2 (ja) |
| EA (1) | EA022755B1 (ja) |
| EC (1) | ECSP11011311A (ja) |
| IL (1) | IL214500A0 (ja) |
| MX (1) | MX2011008485A (ja) |
| NI (1) | NI201100155A (ja) |
| NZ (1) | NZ595046A (ja) |
| PE (1) | PE20120791A1 (ja) |
| SG (2) | SG10201609184PA (ja) |
| TN (1) | TN2011000403A1 (ja) |
| TW (2) | TW201032809A (ja) |
| UY (2) | UY32445A (ja) |
| WO (2) | WO2010093839A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| US20150111930A1 (en) * | 2013-10-23 | 2015-04-23 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
| TW201125562A (en) * | 2009-09-04 | 2011-08-01 | Acorda Therapeutics Inc | Sustained release fampridine treatment in patients with multiple sclerosis |
| CN102442942A (zh) * | 2010-10-08 | 2012-05-09 | 天津和美生物技术有限公司 | 4-氨基吡啶的多晶型物及其制备和应用 |
| EP2995305B1 (en) * | 2011-01-28 | 2020-03-04 | Acorda Therapeutics, Inc. | Use of potassium channel blockers to treat cerebral palsy |
| JP6155284B2 (ja) * | 2012-02-13 | 2017-06-28 | アコルダ セラピュティクス，インコーポレイテッド | アミノピリジンを用いて、多発性硬化症の患者の歩行および／またはバランスの障害を治療する方法 |
| WO2014028387A1 (en) * | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine |
| EP3103096A4 (en) * | 2014-02-04 | 2018-01-03 | Optimata Ltd. | Method and system for prediction of medical treatment effect |
| RU2580837C1 (ru) * | 2015-05-05 | 2016-04-10 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" | Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе |
| CN106511293B (zh) * | 2015-09-11 | 2020-08-04 | 法德生技药品股份有限公司 | 含有达方吡啶的缓释口服制剂及其用途 |
| WO2022124946A1 (ru) * | 2020-12-10 | 2022-06-16 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение |
| CN112914884B (zh) * | 2021-01-19 | 2022-02-11 | 重庆火后草科技有限公司 | 通过稳态时长置信度测量睡眠状态下的体重值的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| US6288026B1 (en) * | 1999-02-24 | 2001-09-11 | Heinrich Exner | Process and composition for treating diseases with an oil-in-water emulsion |
| US8007826B2 (en) * | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) * | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
-
2010
- 2010-02-11 MX MX2011008485A patent/MX2011008485A/es not_active Application Discontinuation
- 2010-02-11 TW TW099104401A patent/TW201032809A/zh unknown
- 2010-02-11 BR BRPI1000030A patent/BRPI1000030A2/pt not_active IP Right Cessation
- 2010-02-11 NZ NZ595046A patent/NZ595046A/xx not_active IP Right Cessation
- 2010-02-11 CN CN201080000861XA patent/CN102046174A/zh active Pending
- 2010-02-11 JP JP2011549357A patent/JP2012517449A/ja active Pending
- 2010-02-11 EA EA201171043A patent/EA022755B1/ru unknown
- 2010-02-11 US US13/148,231 patent/US20120029035A1/en not_active Abandoned
- 2010-02-11 SG SG10201609184PA patent/SG10201609184PA/en unknown
- 2010-02-11 TW TW099104403A patent/TW201034665A/zh unknown
- 2010-02-11 UY UY0001032445A patent/UY32445A/es not_active Application Discontinuation
- 2010-02-11 SG SG2011057783A patent/SG173641A1/en unknown
- 2010-02-11 WO PCT/US2010/023970 patent/WO2010093839A1/en active Application Filing
- 2010-02-11 WO PCT/US2010/023969 patent/WO2010093838A1/en active Application Filing
- 2010-02-11 KR KR1020117021266A patent/KR20120000560A/ko active Application Filing
- 2010-02-11 CA CA2751581A patent/CA2751581A1/en not_active Abandoned
- 2010-02-11 KR KR1020177007639A patent/KR20170034452A/ko active Application Filing
- 2010-02-11 KR KR1020187029188A patent/KR20180114250A/ko not_active Application Discontinuation
- 2010-02-11 UY UY0001032444A patent/UY32444A/es not_active Application Discontinuation
- 2010-02-11 BR BRPI1000031A patent/BRPI1000031A2/pt not_active Application Discontinuation
- 2010-02-11 AU AU2010213663A patent/AU2010213663A1/en not_active Abandoned
- 2010-02-11 CN CN2010800008624A patent/CN101896182A/zh active Pending
- 2010-02-11 PE PE2011001475A patent/PE20120791A1/es not_active Application Discontinuation
- 2010-02-12 AR ARP100100402A patent/AR075413A1/es unknown
-
2011
- 2011-08-07 IL IL214500A patent/IL214500A0/en unknown
- 2011-08-09 NI NI201100155A patent/NI201100155A/es unknown
- 2011-08-10 TN TN2011000403A patent/TN2011000403A1/fr unknown
- 2011-08-10 CL CL2011001927A patent/CL2011001927A1/es unknown
- 2011-09-08 EC EC2011011311A patent/ECSP11011311A/es unknown
- 2011-09-09 CO CO11116663A patent/CO6440534A2/es not_active Application Discontinuation
-
2014
- 2014-11-26 US US14/555,487 patent/US20150313886A1/en not_active Abandoned
-
2016
- 2016-08-25 AU AU2016219650A patent/AU2016219650C1/en not_active Ceased
-
2017
- 2017-05-17 US US15/597,991 patent/US20170319562A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012517449A5 (ja) | ||
| JP2015057451A5 (ja) | ||
| NZ595046A (en) | Compositions and methods for extended therapy with aminopyridines | |
| JP2007238598A5 (ja) | ||
| MX2013002453A (es) | Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos. | |
| EA201100305A1 (ru) | Лечение респираторных заболеваний | |
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| JP2010222367A5 (ja) | ||
| JP2015523407A5 (ja) | ||
| JP2015515475A5 (ja) | ||
| BRPI0922796A2 (pt) | Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2015524444A5 (ja) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| JP2014518860A5 (ja) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2013541583A5 (ja) | ||
| JP2012504560A5 (ja) | ||
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| JP2014521641A5 (ja) | ||
| JP2016530291A5 (ja) |